Baricitinib (also known as LY3009104 or INCB028050) is a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2. Baricitinib is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.
For research use only. We do not sell to patients.
Name | Baricitinib |
---|---|
Iupac Chemical Name | 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]- |
Synonyms | Baricitinib;LY3009104;INCB028050 |
Molecular Formula | C16H17N7O2S |
Molecular Weight | 371.42 |
Smile | C(C)S(=O)(=O)N1CC(C1)(CC#N)N1N=CC(=C1)C=1C2=C(N=CN1)NC=C2 |
InChiKey | XUZMWHLSFXCVMG-UHFFFAOYSA-N |
InChi | InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) |
CAS Number | 1187594-09-7 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | white solid |
---|---|
Purity | 98% |
Storage | 3 years -20ºCpowder |
Solubility | 5mg/ml in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |